Novo Nordisk Signs US$252.6 M Deal with EraCal to Boost Obesity Portfolio
By Amit Kaushik
Pharma Deals Review: Vol 2024 Issue 2 (Table of Contents)
Published: 8 Feb-2024
DOI: 10.3833/pdr.v2024.i2.2852 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a groundbreaking move with the potential to revolutionise the treatment of obesity, Novo Nordisk has entered into a licensing agreement with EraCal Therapeutics to develop and commercialise a small molecule investigational obesity therapeutic to control appetite and body weight...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS